Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323164 | 0.95 | GLA (0.61) | GLATP53ALDH1A1RAB9ANPC1 | |
| SCHEMBL2330609 | 0.90 | ALDH1A1 (0.59) | GLATP53ALDH1A1RAB9ANPC1 | |
| SCHEMBL4589453 | 0.88 | ALDH1A1 (0.57) | GLATP53ALDH1A1RAB9ANPC1 | |
| SCHEMBL2325922 | 0.88 | NPC1 (0.49) | GLAALDH1A1RAB9ANPC1CASP3 | |
| SCHEMBL2329222 | 0.88 | RAB9A (0.52) | GLATP53ALDH1A1RAB9ANPC1 | |
| SCHEMBL2326240 | 0.86 | ALDH1A1 (0.52) | TP53ALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL8027341 | 0.85 | RAB9A (0.60) | ALDH1A1RAB9ANPC1CASP3SENP8 | |
| SCHEMBL8026811 | 0.85 | ALDH1A1 (0.48) | TP53ALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL2326385 | 0.85 | ALDH1A1 (0.59) | GLATP53ALDH1A1RAB9AMAPT | |
| SCHEMBL8011388 | 0.85 | TP53 (0.66) | GLATP53ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117263869-A | Method for synthesizing N-aryl benzimidazole derivative | 郑州轻工业大学 | 2023-12-22 | — | — | CN | disclosed |
| EP-1246808-B1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | BAYER SCHERING PHARMA AG (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7345075-B2 | 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester; antiinflammatory agents; microglia activators; neurodegenerative diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7329679-B2 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7115645-B2 | 1,2 diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1246808-A1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | SCHERING AG | 2002-01-17 | — | — | US | disclosed |
| WO-2001051473-A1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-07-19 | — | — | WO | disclosed |
| US-6030992-A | ANTAGONISTS FOR THE BINDING OF NEUROKININ-2 RECEPTOR; SLEEP DISORDERS; BENZIMIDES, 2- OR 3-ALKOXYBENZIMIDES AND 2,3-DIALKOXYBENZIMIDES | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-6025379-A | A SUBSTITUTED BENZIMIDAZOLE, TACHYKININ RECEPTOR ANTAGONISTS, | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| US-5552426-A | NERVOUS SYSTEM DISORDERS USING IMIDAZOLE DERIVITIVES | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0694535-A1 | Non-peptidyl tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | CYP2E1, CYP1B1, CYP1A1 | GLA 1016/4885TP53 4468/4885ALDH1A1 29/4885 |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | GLA 979/4885TP53 4001/4885ALDH1A1 118/4885 |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | GLA 979/4885TP53 4001/4885ALDH1A1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.